{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:55:27Z","timestamp":1746190527520},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"Supplement_A","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes of Health and European Union"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/eurheartj\/suy031","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:01:44Z","timestamp":1551178904000},"page":"A41-A47","source":"Crossref","is-referenced-by-count":6,"title":["New treatments for hyperkalaemia: clinical use in cardiology"],"prefix":"10.1093","volume":"21","author":[{"given":"Shilpa","family":"Vijayakumar","sequence":"first","affiliation":[{"name":"Department of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi, 2500 North State Street, Jackson, MS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charit\u00e9 Universit\u00e4tsmedizin Berlin, Germany; and"},{"name":"Department of Cardiology, University\u00e4tsmedizin G\u00f6ttingen (UMG), G\u00f6ttingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022808504570800_suy031-B1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B3","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ehf2.12229","article-title":"Diuretic dosing in heart failure: more data are needed","volume":"5","author":"De Vecchis","year":"2018","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B11","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","article-title":"Management of severe hyperkalemia","volume":"36","author":"Weisberg","year":"2008","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ehf2.12221","article-title":"The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure","volume":"5","author":"Okabe","year":"2018","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/eurjhf\/hfr121","article-title":"Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis","volume":"13","author":"Yilmaz","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.667","article-title":"Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function","volume":"19","author":"Breidthardt","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B15","first-page":"43","article-title":"Potassium-binding agents for the clinical management of hyperkalemia","volume":"41","author":"Chaitman","year":"2016","journal-title":"P T"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B16","first-page":"296","article-title":"Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia","volume":"68","author":"Batterink","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-200105000-00011","article-title":"Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings","volume":"25","author":"Abraham","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14656566.2016.1190333","article-title":"Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer","volume":"17","author":"Epstein","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/164_2017_25","article-title":"Role of hyperkalemia in heart failure and the therapeutic use of potassium binders","volume":"243","author":"Sarwar","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B24","doi-asserted-by":"crossref","first-page":"e114686.","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B25","volume-title":"Full Prescribing Information","year":"2015"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B26","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B29","volume-title":"2018 Full Prescribing Information.","year":"6 2018"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, SZC, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-016-9384-x","article-title":"Updates in hyperkalemia: outcomes and therapeutic strategies","volume":"18","author":"Kovesdy","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B36","volume-title":"Poster Presentation at American Society of Nephrology Kidney Week 2017","author":"Fishbane","year":"2017"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B37","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B40","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"Authors\/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/pgmj.2008.072058","article-title":"Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism","volume":"86","author":"Poggio","year":"2010","journal-title":"Postgrad Med J"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B42","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1525-139X.2001.00087.x","article-title":"Hyperkalemia in dialysis patients","volume":"14","author":"Ahmed","year":"2001","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B46","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","article-title":"Metabolic complications in elderly adults with chronic kidney disease","volume":"60","author":"Drawz","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B49","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cardfail.2006.01.013","article-title":"Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis","volume":"12","author":"Baliga","year":"2006","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B51","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","article-title":"Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone","volume":"18","author":"Cruz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","article-title":"Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil","volume":"30","author":"Saito","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0002-9149(02)02581-X","article-title":"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease","volume":"90","author":"Obialo","year":"2002","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B55","first-page":"208","article-title":"Risk calculation for hyperkalaemia in heart failure patients","volume":"65","author":"Vereijken","year":"2007","journal-title":"Neth J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B56","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurjhf\/hfs145","article-title":"Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial","volume":"14","author":"Kiernan","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","article-title":"Serum potassium levels and mortality in acute myocardial infarction","volume":"307","author":"Goyal","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B59","first-page":"104","article-title":"Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data","volume":"38","author":"Krogager","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B60","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B61","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident Hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B63","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1217","article-title":"Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists","author":"Butler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B66","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ehf2.12237","article-title":"Muscle wasting and sarcopenia in heart failure and beyond: update","volume":"4","author":"Springer","year":"2017","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13539-014-0152-z","article-title":"Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones","volume":"5","author":"Josiak","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jcsm.12192","article-title":"Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia","volume":"8","author":"Morley","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B70","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jcsm.12193","article-title":"Muscle wasting in young patients with dilated cardiomyopathy","volume":"8","author":"Hajahmadi","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcsm.12167","article-title":"Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J","volume":"7","author":"von Haehling","year":"2016","journal-title":"Cachexia Sarcopenia Muscle"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/clc.20284","article-title":"Safety of spironolactone use in ambulatory heart failure patients","volume":"31","author":"Lopes","year":"2008","journal-title":"Clin Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B73","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.ijcard.2013.12.076","article-title":"Gap between clinical guidelines and practice: the case of aldosterone-antagonists in patients with myocardial infarction","volume":"172","author":"Shore","year":"2014","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cardfail.2014.01.017","article-title":"Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience","volume":"20","author":"Chamsi-Pasha","year":"2014","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B77","doi-asserted-by":"crossref","first-page":"e7473.","DOI":"10.1136\/bmj.e7473","article-title":"Resistant hypertension","volume":"345","author":"Myat","year":"2012","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B78","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B79","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B80","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B82","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B83","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B84","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B85","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504570800_suy031-B86","doi-asserted-by":"crossref","first-page":"A14271","DOI":"10.1161\/circ.132.suppl_3.14271","article-title":"Patiromer controls hyperkalemia in resistant hypertensive patients on RAASi, with diabetic kidney disease","volume":"132","author":"Epstein","year":"2015","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_A\/A41\/27994223\/suy031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T03:50:55Z","timestamp":1721015455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_A\/A41\/5364186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":86,"journal-issue":{"issue":"Supplement_A","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suy031","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}